InvestSMART

Pro Medicus Limited (ASX: PME) - Announcements

Current share price for PME : $206.010 7.16 (3.60%)+

ASX company news and announcements for Pro Medicus Limited (PME) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pro Medicus Limited (PME) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pro Medicus Limited (PME), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pro Medicus Limited (PME)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21,522 Dividend/Distribution - PME 19 Aug 2016 10:01AM $5.840 $206.010 risen by 3,427.57%
$21,522 Company Announcement - Full Year Results 19 Aug 2016 9:51AM $5.840 $206.010 risen by 3,427.57%
$21,522 Full Year Statutory Accounts 19 Aug 2016 9:48AM $5.840 $206.010 risen by 3,427.57%
$21,522 Appendix 4G and Corporate Governance Statement 19 Aug 2016 9:48AM $5.840 $206.010 risen by 3,427.57%
$21,522 Appendix 4E - Preliminary Final Report 19 Aug 2016 9:46AM $5.840 $206.010 risen by 3,427.57%
$21,522 Open Briefing - CEO on FY16 results 19 Aug 2016 12:36AM $5.900 $206.010 risen by 3,391.69%
$21,522 Open Briefing - CEO on Significant New contract 4 Jul 2016 11:31AM $5.120 $206.010 risen by 3,923.63%
$21,522 PME signs key US contract 4 Jul 2016 9:34AM $4.710 $206.010 risen by 4,273.89%
$21,522 Initial Director's Interest Notice 4 May 2016 10:18AM $4.430 $206.010 risen by 4,550.34%
$21,522 PME signs $7M deal with FMOLHS 27 Apr 2016 9:45AM $3.960 $206.010 risen by 5,102.27%
$21,522 PME appoints new Non-Executive Director 20 Apr 2016 9:54AM $3.950 $206.010 risen by 5,115.44%
$21,522 Open Briefing - CEO on Mercy contract 4 Apr 2016 10:11AM $3.420 $206.010 risen by 5,923.68%
$21,522 PME signs $21M deal with Mercy Health 4 Apr 2016 9:19AM $3.420 $206.010 risen by 5,923.68%
$21,522 Appendix 3B - Exercise of share options 22 Mar 2016 9:30AM $3.390 $206.010 risen by 5,976.99%
$21,522 On market share buy-back 17 Mar 2016 9:37AM $3.160 $206.010 risen by 6,419.30%
$21,522 CEO Presentation - ASX Spotlight Conference New York 4 Mar 2016 8:25AM $2.880 $206.010 risen by 7,053.13%
$21,522 Update - Dividend/Distribution - PME 19 Feb 2016 4:53PM $3.010 $206.010 risen by 6,744.19%
$21,522 Open Briefing - CEO on HY16 results 19 Feb 2016 11:03AM $3.100 $206.010 risen by 6,545.48%
$21,522 Dividend/Distribution - PME 19 Feb 2016 10:11AM $3.120 $206.010 risen by 6,502.88%
$21,522 Company Announcement - Interim Results 19 Feb 2016 9:47AM $3.120 $206.010 risen by 6,502.88%
$21,522 Half Year Accounts 19 Feb 2016 9:46AM $3.120 $206.010 risen by 6,502.88%
$21,522 Appendix 4D 19 Feb 2016 9:46AM $3.120 $206.010 risen by 6,502.88%
$21,522 ACR & UF Health select Visage 7 for key training program 11 Feb 2016 9:58AM $2.870 $206.010 risen by 7,078.05%
$21,522 Appendix 3B - Exercise of share options 23 Nov 2015 12:54PM $3.480 $206.010 risen by 5,819.83%
$21,522 Results of AGM - 2015 20 Nov 2015 11:33AM $3.270 $206.010 risen by 6,200%

526 - 550 of 678 results

Page 22 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.